

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 07-1052-WO-US)**

In the Application of:)
Daniel Christopher Brookings, et al.)
Serial No.: 10/561,052) Examiner: Niloofar Rahmani
Filing Date: October 10, 2006) Group Art Unit: 1625
For: Thienopyridone Derivatives as) Confirmation No. 3974
Kinase Inhibitors)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Pursuant to the office action response, submitted October 7, 2008, Applicants hereby submit a Terminal Disclaimer to obviate a double patenting rejection over a "prior" patent. In the office action dated July 7, 2008, the Office rejected the claims of the instant application in light of US2006/0004025, and required a Terminal Disclaimer. Since the time of that rejection, the cited application, co-owned by Applicant, has now matured into U.S. Patent No. 7,423,047, so Applicants are submitting a Terminal Disclaimer with respect to the patent, rather than the application.

If the Examiner believes it would expedite the allowance of the application, the Examiner is invited to contact the undersigned at the number below. Please charge any necessary fees to deposit account no. 13-2490.

Respectfully submitted,

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP

Date: January 5, 2009

By:/Marcia Ireland Rosenfeld/
Marcia Ireland Rosenfeld
Registration No. 60,679
312-913-0001